Home / Deep Research / Pontocerebellar Hypoplasia

Pontocerebellar Hypoplasia

1. Disease Information

2026-04-26
Falcon MONDO:0020135 Model: Edison Scientific Literature 30 citations

1. Disease Information

1.1 What is the disease?

Pontocerebellar hypoplasia (PCH) is an umbrella term for a heterogeneous group of (usually prenatal or early‑infancy onset) neurodevelopmental disorders characterized by reduced volume (hypoplasia) of the pons and cerebellum, often with progressive microcephaly and variable supratentorial involvement; many classic subtypes are neurodegenerative. (dijk2018what’snewin pages 1-3, cavusoglu2024evaluationofthe pages 1-2)

A key recent expert framing is that “PCH” should be used primarily as a radiologic descriptor (reduced-volume pons and cerebellum), because many monogenic, chromosomal, and acquired conditions can produce a PCH-like imaging pattern. (zakaria2024classic“pch”genes pages 1-4)

Direct abstract quote (radiologic descriptor and heterogeneity): “As a descriptive term, PCH refers to pons and cerebellum of reduced volume… many other disorders can result in a similar imaging appearance.” (zakaria2024classic“pch”genes pages 1-4)

1.2 Key identifiers

  • MONDO ID: not available in retrieved sources.
  • OMIM / Orphanet / ICD‑10/ICD‑11 / MeSH: not available in retrieved sources (codes not explicitly stated in the retrieved full text excerpts).

1.3 Common synonyms / alternative names

1.4 Evidence source type

The retrieved evidence is primarily: * Aggregated disease-level synthesis from reviews. (dijk2018what’snewin pages 1-3, kukulka2025pontocerebellarhypoplasiaa pages 11-13) * Human cohorts/case series with imaging + genetic evaluation. (zakaria2024classic“pch”genes pages 1-4, cavusoglu2024evaluationofthe pages 1-2) * Human iPSC/organoid functional modeling. (kagermeier2024humanorganoidmodel pages 1-2) * ClinicalTrials.gov interventional/observational records (not PCH‑specific drug approvals). (NCT04378075 chunk 1, NCT03572868 chunk 1)

2. Etiology

2.1 Disease causal factors

Primary cause: inherited genetic variants affecting fundamental cellular processes, with a strong over‑representation of genes involved in RNA processing and translation, especially tRNA biology (splicing and aminoacylation), and additional causes in mitochondrial function and basic metabolism. (dijk2018what’snewin pages 10-11, ghasemi2024broadeningthephenotype pages 11-13)

PCH is also a radiologic pattern that can result from: * Chromosomal abnormalities, * Monogenic disorders outside classic PCH genes, and * Acquired insults (e.g., prematurity, hypoxic‑ischemic injury), depending on the cohort studied. (zakaria2024classic“pch”genes pages 1-4)

2.2 Risk factors

  • Genetic / familial: predominance of autosomal recessive inheritance in classic PCH types; high rates of homozygosity and consanguinity in some populations/cohorts. In a Turkish multicenter genetically confirmed cohort (n=64), homozygous mutation occurred in 89.1% and consanguinity in 79.7%. (cavusoglu2024evaluationofthe pages 1-2)
  • Non-genetic (for radiologic PCH phenotype): acquired etiologies can contribute a minority of radiologic PCH cases (10.5% acquired in one imaging‑defined cohort). (zakaria2024classic“pch”genes pages 17-20)

2.3 Protective factors

No protective genetic variants or modifiable protective environmental factors were identified in the retrieved evidence set.

2.4 Gene–environment interactions

No explicit gene–environment interaction evidence was identified in the retrieved evidence set.

3. Phenotypes (clinical + suggested HPO terms)

3.1 Core phenotypic spectrum (human cohorts)

Across cohorts, common phenotypes include global developmental delay/intellectual disability, abnormal tone, microcephaly, seizures, feeding and respiratory problems, and variable visual/hearing impairment. (zakaria2024classic“pch”genes pages 4-7, cavusoglu2024evaluationofthe pages 1-2)

Recent quantitative phenotype data (2024 cohorts): * Genetically confirmed PCH cohort, Turkey (n=64): microcephaly 91.3%, psychomotor retardation 98.4%, abnormal neurologic findings 100%, seizures 63.8%. (cavusoglu2024evaluationofthe pages 1-2) * Radiologic PCH cohort (n=38): global developmental delay in all; feeding difficulties 76%, respiratory issues 64%; 50% non-verbal, 64% non-ambulatory, 45% gastrostomy feeding; ~1/3 mortality with median age at death 8 months. (zakaria2024classic“pch”genes pages 4-7, zakaria2024classic“pch”genes pages 1-4)

3.2 Onset, severity, progression

  • Onset is often prenatal or neonatal/infancy, consistent with fetal/postnatal neurodevelopmental disruption and/or early neurodegeneration. (dijk2018what’snewin pages 1-3)
  • Imaging and clinical features may evolve over time, supporting serial follow‑up imaging. (kukulka2025pontocerebellarhypoplasiaa pages 11-13)

3.3 Suggested HPO terms (examples)

  • Pontocerebellar hypoplasia: HP:0001320 (term name; code not verified in retrieved evidence)
  • Cerebellar hypoplasia: HP:0001321 (term name; code not verified)
  • Hypoplasia of the pons: (HPO term name; code not verified)
  • Microcephaly: HP:0000252 (term name; code not verified)
  • Global developmental delay: HP:0001263 (term name; code not verified)
  • Seizures: HP:0001250 (term name; code not verified)
  • Hypotonia: HP:0001252 (term name; code not verified)
  • Feeding difficulties / dysphagia: HP:0011968 / HP:0002015 (term names; codes not verified)
  • Respiratory insufficiency / apnea: HP:0002093 / HP:0002104 (term names; codes not verified)
  • Optic atrophy / visual impairment: HP:0000648 / HP:0000505 (term names; codes not verified)

Note: HPO term names are provided to support knowledge-base mapping, but exact HPO IDs should be validated against the current HPO release because IDs were not provided in the retrieved sources.

3.4 Quality of life impact

Severe motor and communication impairment is common in imaging- and genetics-defined cohorts (e.g., non-ambulatory 64% and non-verbal 50% in a radiologic PCH cohort), implying profound caregiver and daily-function impact. (zakaria2024classic“pch”genes pages 4-7)

4. Genetic / Molecular Information

4.1 Causal genes (examples emphasized in 2023–2024 evidence)

Recent large cohorts and updated reviews highlight recurrent genes including CLP1, TSEN54, EXOSC3, RARS2, AMPD2, with many additional rare causes. (cavusoglu2024evaluationofthe pages 2-5, ghasemi2024broadeningthephenotype pages 1-2)

Cohort gene frequencies (Turkey, n=64): CLP1 26.56%; EXOSC3 10.9%; TSEN54 9.3%; RARS2 7.8%. (cavusoglu2024evaluationofthe pages 2-5)

4.2 Pathogenic variants (examples)

4.3 Functional consequences (high-level)

A unifying theme is dysfunction in RNA/tRNA processing and translation, including: * tRNA intron excision (TSEN complex) and post-splicing processing (CLP1); defects are hypothesized to affect translation capacity and neurodevelopmental cell states. (dijk2018what’snewin pages 10-11, kagermeier2024humanorganoidmodel pages 1-2) * Mitochondrial tRNA aminoacylation (RARS2) affecting mitochondrial translation and respiratory chain function. (nicolle2023anoncodingvariant pages 1-2, ghasemi2024broadeningthephenotype pages 11-13) * RNA exosome function (EXOSC3 and related EXOSC genes) affecting RNA processing and ribosome biogenesis signaling. (cavusoglu2024evaluationofthe pages 10-11)

4.4 Modifier genes / epigenetics / chromosomal abnormalities

  • Modifier genes / epigenetics: not identified in retrieved evidence.
  • Chromosomal abnormalities: contribute substantially to imaging-defined PCH: 21% chromosomal etiologies in a radiologic cohort (n=38). (zakaria2024classic“pch”genes pages 1-4)

5. Environmental Information

PCH is primarily genetic; no consistent environmental/lifestyle contributors were identified in the retrieved sources. However, acquired causes can mimic radiologic PCH in some patients (e.g., prematurity/hypoxic injury comprising a minority in an imaging cohort). (zakaria2024classic“pch”genes pages 17-20)

6. Mechanism / Pathophysiology

6.1 Mechanistic themes and causal chains

Upstream trigger: biallelic pathogenic variants in genes involved in core RNA processing/translation/metabolism → cell-type and developmental time-window vulnerability in hindbrain/cerebellar development → impaired progenitor proliferation/differentiation and/or neurodegeneration → reduced pons/cerebellar growth and associated supratentorial abnormalities → severe motor/cognitive impairment, seizures, feeding/respiratory complications. (dijk2018what’snewin pages 10-11, kagermeier2024humanorganoidmodel pages 1-2)

Direct abstract quote (mechanistic clarification for a noncoding variant): the RARS2 Kozak variant “disrupts the consensus Kozak sequence, and has a major impact on RARS2 protein translation.” (nicolle2023anoncodingvariant pages 1-2)

6.2 Example: TSEN54 (PCH2A) — neurodevelopmental mechanism supported by organoids (2024)

A 2024 human iPSC-derived regional organoid model for genetically homogeneous PCH2A (TSEN54 p.Ala307Ser homozygosity) recapitulated brain-region specific hypoplasia and implicated altered progenitor proliferation kinetics rather than apoptosis as an early driver.

Direct abstract quote: “PCH2a cerebellar organoids were reduced in size compared to controls starting early in differentiation… Although PCH2a cerebellar organoids did not upregulate apoptosis, their stem cell zones showed altered proliferation kinetics…” (kagermeier2024humanorganoidmodel pages 1-2)

Key quantitative cellular readouts included marked changes in SOX2+ progenitor rosette dynamics (e.g., D30 rosette area 24±3.07% vs 2±0.53% in controls, reversing by D50). (kagermeier2024humanorganoidmodel pages 6-8)

6.3 Example: CLP1 (PCH10) — tRNA processing and neurodegeneration

CLP1 is described as an RNA kinase required for tRNA splicing/maturation; pathogenic variants impair kinase activity and tRNA processing, with proposed mechanisms including abnormal accumulation of tRNA fragments and broader transcriptional consequences (e.g., reduced mRNA isoform diversity). (cavusoglu2024evaluationofthe pages 11-12)

6.4 Example: EXOSC3 (PCH1B) — RNA exosome/ribosome biogenesis signaling

EXOSC genes encode core exosome proteins; exosome dysfunction is linked (via cited literature within cohort review) to disrupted ribosome biogenesis and p53-dependent signaling, offering a mechanistic bridge from RNA processing defects to neurodevelopmental/neurodegenerative phenotypes. (cavusoglu2024evaluationofthe pages 10-11)

6.5 Example: RARS2 (PCH6) — mitochondrial translation and metabolic decompensation

RARS2 encodes mitochondrial arginyl‑tRNA synthetase; PCH6 is framed as a mitochondrial disorder with epilepsy/encephalopathy and potential lactic acidosis/respiratory chain defects. (ghasemi2024broadeningthephenotype pages 11-13, dijk2018what’snewin pages 6-7)

6.6 Suggested ontology mappings

GO Biological Process (examples; verify IDs): * tRNA processing / tRNA splicing * mitochondrial translation * RNA catabolic process / RNA processing * ribosome biogenesis * neural precursor cell proliferation

Cell types (Cell Ontology; examples): * Purkinje cell (cerebellum) (implicated by high cerebellar vulnerability and prior models; Purkinje markers present in organoids) (kagermeier2024humanorganoidmodel pages 2-4) * Neural progenitor cell / radial glia-like progenitors (SOX2+ rosettes) (kagermeier2024humanorganoidmodel pages 6-8)

Subcellular components (GO CC; examples): * mitochondrion (RARS2) * cytosol/nucleus (RNA processing)

7. Anatomical Structures Affected

7.1 Organ/system level

Primary: central nervous system, especially hindbrain. * Pons and cerebellum are obligatorily reduced in classic definitions and imaging cohorts. (zakaria2024classic“pch”genes pages 1-4) Secondary/variable: supratentorial structures (corpus callosum, cortex, white matter) frequently involved in radiologic cohorts. (zakaria2024classic“pch”genes pages 4-7)

7.2 Suggested anatomy ontology mappings

  • UBERON (examples; verify IDs): pons, cerebellum, cerebellar vermis, cerebellar hemisphere, corpus callosum, cerebral white matter.

8. Temporal Development

8.1 Onset

Typically prenatal detection is possible, but reductions may be subtle early; fetal MRI at 20–25 weeks and repeat at 30–34 weeks is proposed for suspected cases. (kukulka2025pontocerebellarhypoplasiaa pages 11-13)

8.2 Progression

Serial imaging is emphasized because reduced growth trajectories or progressive volume loss may be necessary to establish the diagnosis and characterize evolving brain involvement. (kukulka2025pontocerebellarhypoplasiaa pages 11-13)

9. Inheritance and Population

9.1 Inheritance patterns

Classic PCH subtypes are predominantly autosomal recessive. (dijk2018what’snewin pages 1-3) Population structure can strongly influence apparent frequencies (e.g., high consanguinity and recurrent founder variants in certain cohorts). (cavusoglu2024evaluationofthe pages 1-2)

9.2 Epidemiology

Incidence/prevalence estimates were not available in the retrieved evidence set. An older review explicitly states that “The incidence of each subtype is unknown.” ()

10. Diagnostics

10.1 Imaging (MRI) and radiologic criteria

MRI is central. One cohort operationalized criteria including: * Pons hypoplasia defined by CC pons:CC midbrain <1.5 and/or AP pons < AP midbrain. * Vermis hypoplasia defined as vermis height or AP vermis diameter <3rd percentile versus age/sex norms. (zakaria2024classic“pch”genes pages 1-4)

Radiologic patterns used for subtype/differential orientation include “dragonfly” and “butterfly” cerebellar configurations and a “figure-of-8” midbrain pattern (notably associated with AMPD2/PCH9 in reviewed sources). (dijk2018what’snewin pages 6-7, cavusoglu2024evaluationofthe pages 2-5)

10.2 Genetic testing approach

Because classic PCH genes may explain only a minority of imaging-defined PCH, broad genetic testing is recommended: * Chromosomal microarray (CMA) plus exome sequencing or multigene panels in individuals with PCH-like imaging. (zakaria2024classic“pch”genes pages 1-4)

Where a distinctive imaging/clinical profile exists, targeted testing for known recurrent variants (e.g., TSEN54 p.A307S) is suggested in reviews, with WES for broader detection given ongoing gene discovery. (dijk2018what’snewin pages 13-14)

10.3 Metabolic / laboratory workup

A Turkish multicenter study describes routine biochemical/metabolic investigations in evaluation, listing tests such as amino acids (urine/blood), tandem MS, organic acids, VLCFA, biotinidase, and transferrin studies. (cavusoglu2024evaluationofthe pages 1-2)

10.4 Differential diagnosis

Differentials include acquired and metabolic mimics and numerous genetic disorders producing PCH-like imaging (e.g., tubulinopathies, CASK, RELN, VLDLR-related disorders, and congenital disorders of glycosylation). (zakaria2024classic“pch”genes pages 1-4, kukulka2025pontocerebellarhypoplasiaa pages 6-7)

11. Outcome / Prognosis

11.1 Survival and mortality (recent data)

Prognosis is often poor, but varies widely by etiology and subtype.

Radiologic PCH cohort (n=38, 2024): mortality 36%, with median age at death 8 months (mean 17 months). (zakaria2024classic“pch”genes pages 4-7)

Older reviews characterize prognosis as poor with frequent death in infancy/childhood for classic subtypes, consistent with the above cohort. (dijk2018what’snewin pages 1-3)

11.2 Morbidity and function

Severe disability is common in imaging-defined cohorts: non-verbal 50%, non-ambulatory 64%, and gastrostomy feeding 45% were reported in one radiologic cohort. (zakaria2024classic“pch”genes pages 4-7)

12. Treatment

12.1 Standard of care: supportive / symptomatic

No disease-modifying therapies were identified in the retrieved clinical literature excerpts; management is multidisciplinary supportive care addressing feeding, ventilation/respiratory issues, seizures, movement disorders, orthopedic complications, and palliative care as needed. (kukulka2025pontocerebellarhypoplasiaa pages 11-13, dijk2018what’snewin pages 6-7)

Specific supportive recommendations highlighted in a review include sleep monitoring for life‑threatening apnea in PCH2A, common need for gavage/PEG feeding, physiotherapy and assistive devices, and symptomatic seizure management (phenobarbital/topiramate mentioned in reported series). (dijk2018what’snewin pages 6-7)

Suggested MAXO terms (examples; verify IDs): * gastrostomy tube placement * enteral nutrition * antiepileptic drug therapy * ventilatory support * physical therapy / occupational therapy / speech therapy * palliative care

12.2 Experimental / clinical trials (real-world implementations)

Vatiquinone (PTC743/EPI-743) trial including PCH6 (RARS2): ClinicalTrials.gov NCT04378075 evaluated vatiquinone for mitochondrial disease with refractory epilepsy and explicitly included “Pontocerebellar Hypoplasia Type 6” among eligible conditions. It was a randomized, double‑blind, placebo‑controlled Phase 2/3 trial (n=68), with primary outcome percent change in observable motor seizure frequency at Week 24; it started 2020‑09‑28, primary completion 2023‑03‑18, completion 2023‑12‑27, and was terminated due to sponsor decision. (NCT04378075 chunk 1, NCT04378075 chunk 2)

URL: https://clinicaltrials.gov/study/NCT04378075 (record referenced by retrieved excerpts) (NCT04378075 chunk 1)

An observational study of isolated small cerebellum (NCT03572868) is relevant to cerebellar hypoplasia outcomes broadly but is not genotype-specific to PCH. (NCT03572868 chunk 1)

URL: https://clinicaltrials.gov/study/NCT03572868 (NCT03572868 chunk 1)

13. Prevention

No primary prevention is available for most PCH because it is primarily genetic. Secondary prevention focuses on genetic counseling and availability of prenatal testing once familial pathogenic variants are known (a capability emphasized historically in foundational reviews). ()

14. Other Species / Natural Disease

No naturally occurring veterinary PCH syndromes were characterized in the retrieved excerpts. However, cross-species modeling is discussed for TSEN54 and related pathways (with limitations due to conservation). (kagermeier2024humanorganoidmodel pages 2-2)

15. Model Organisms / Model Systems

15.1 Human iPSC / organoid models (2024)

A 2024 Disease Models & Mechanisms study established patient-derived iPSC lines (TSEN54 p.Ala307Ser homozygous) and generated cerebellar and neocortical organoids reproducing region‑specific growth deficits and altered progenitor dynamics without increased apoptosis. (kagermeier2024humanorganoidmodel pages 1-2, kagermeier2024humanorganoidmodel pages 6-8)

15.2 Animal models (limitations + utility)

Animal models for TSEN54 loss can be embryonic lethal and may not reproduce the human region-specific phenotype; species differences in residue conservation are highlighted as a rationale for human organoid modeling. (kagermeier2024humanorganoidmodel pages 2-2)

Recent developments and expert analysis (prioritizing 2023–2024)

1) Reframing PCH as a radiologic pattern with diverse etiologies (2024): A 38‑patient cohort concluded classic OMIM PCH genes underlie only a minority of radiologic PCH and recommended broad testing (CMA + exome/panels). This shifts clinical practice away from assuming “classic PCH” when imaging shows pontocerebellar hypoplasia. (zakaria2024classic“pch”genes pages 1-4)

2) Largest retrieved genetically confirmed national cohort (2024, Turkey): CLP1 was the most common gene in this cohort, with high homozygosity and consanguinity rates, emphasizing how founder effects and population structure shape observed gene distributions. (cavusoglu2024evaluationofthe pages 1-2, cavusoglu2024evaluationofthe pages 2-5)

3) Human mechanistic modeling advances (2024): Regionalized neural organoids for PCH2A provide a direct human experimental system supporting a neurodevelopmental progenitor proliferation mechanism (at least early), which can inform target discovery and phenotypic screening endpoints. (kagermeier2024humanorganoidmodel pages 1-2, kagermeier2024humanorganoidmodel pages 6-8)

4) Noncoding variant interpretation (2023): The RARS2 Kozak-sequence work demonstrates that pathogenicity in PCH can arise from variants outside coding regions and highlights limitations of mRNA-level assessment alone for noncoding variants. (nicolle2023anoncodingvariant pages 1-2)

Structured summary table

Table (click to expand)
PCH entity Key gene(s) / representative variant(s) Inheritance (if stated) Hallmark imaging patterns Key clinical features Key quantitative statistics Primary supporting citation IDs
Radiologic PCH cohort (Zakaria 2024) Heterogeneous causes; classic OMIM PCH genes rare (only 1 patient). Identified etiologies included chromosomal causes and monogenic causes such as POMGNT1, CASK, AIMP1, ASPM, CHD7, DHCR7, NFIX, OFD1, VLDLR Not uniform; chromosomal, monogenic, and acquired etiologies all represented Universal pons + cerebellar vermis hypoplasia; cerebellar hemisphere hypoplasia in many; “butterfly” pattern common among hemisphere-hypoplasia cases; supratentorial anomalies frequent; no cerebellar atrophy in this cohort Global developmental delay in all; frequent feeding and respiratory problems, hypotonia, microcephaly, epilepsy, sensory impairment; poor neurodevelopmental outcomes n=38; pons/vermis hypoplasia 100%; hemisphere hypoplasia 63%; supratentorial anomalies 71%; etiologic diagnosis 65% overall (21% chromosomal, 34% monogenic, 10% acquired); non-verbal 50%; non-ambulatory 64%; gastrostomy 45%; mortality 36%, median age at death 8 months (zakaria2024classic“pch”genes pages 4-7, zakaria2024classic“pch”genes pages 1-4) (zakaria2024classic“pch”genes pages 4-7, zakaria2024classic“pch”genes pages 1-4, zakaria2024classic“pch”genes pages 17-20)
Genetically confirmed Turkish PCH cohort (Cavusoglu 2024) Most common CLP1 c.419G>A (p.Arg140His); recurrent TSEN54 c.919G>T (p.Ala307Ser); also EXOSC3, RARS2, MINPP1, AMPD2, CHMP1A, SEPSECS, TSEN2, TSEN34, TBC1D23, HEATR5B Predominantly autosomal recessive; homozygous variants common “Dragonfly” cerebellum (esp. TSEN54/AMPD2), “butterfly” pattern (EXOSC3), flattened pons (CLP1), “figure-of-8” midbrain (AMPD2) Nearly universal neurodevelopmental impairment with microcephaly, seizures, eye abnormalities, cerebellar/brainstem signs, hypotonia/spasticity; broad genotype-phenotype variability n=64; female 43.8%, male 56.3%; homozygous mutations 89.1%; consanguinity 79.7%; microcephaly 91.3%; psychomotor retardation 98.4%; abnormal neurologic findings 100%; seizures 63.8% overall; brainstem signs 55.3%; cerebellar deficits 67.3%; eye abnormalities 69.8%; CLP1 cases 26.56% of cohort (cavusoglu2024evaluationofthe pages 1-2, cavusoglu2024evaluationofthe pages 2-5) (cavusoglu2024evaluationofthe pages 1-2, cavusoglu2024evaluationofthe pages 2-5, cavusoglu2024evaluationofthe pages 11-12, cavusoglu2024evaluationofthe pages 10-11, cavusoglu2024evaluationofthe pages 12-14)
PCH2A / TSEN54-associated disease TSEN54 founder missense c.919G>T (p.Ala307Ser); more severe related phenotypes with p.A307S plus loss-of-function/splice variants in TSEN54 Autosomal recessive Classic “dragonfly” cerebellar pattern; pontocerebellar hypoplasia/atrophy; progressive microcephaly Prenatal/infantile onset; severe developmental impairment, extrapyramidal dyskinesia/choreoathetosis, feeding problems, sleep apnea, seizures; genotype-phenotype correlation with more severe neonatal phenotypes for TSEN54 compound heterozygosity Founder genotype highlighted across series; severe structural abnormalities often present at birth; exact cohort size varies by study rather than a single pooled estimate (cavusoglu2024evaluationofthe pages 1-2, dijk2018what’snewin pages 1-3, dijk2018what’snewin pages 3-5, ghasemi2024broadeningthephenotype pages 6-7, dijk2018what’snewin pages 13-14) (cavusoglu2024evaluationofthe pages 1-2, dijk2018what’snewin pages 1-3, dijk2018what’snewin pages 3-5, ghasemi2024broadeningthephenotype pages 6-7, dijk2018what’snewin pages 13-14)
PCH2A human organoid model (Kagermeier 2024) Patient-derived iPSCs with homozygous TSEN54 c.919G>T (p.Ala307Ser) Human model of an AR disorder Region-specific size reduction reproduced in vitro: cerebellar organoids smaller early; neocortical organoids milder/later deficit; altered SOX2+ rosette dynamics rather than increased apoptosis Supports a neurodevelopmental component with altered neural progenitor proliferation kinetics and cerebellar-selective vulnerability 3 patient lines + 3 controls; cerebellar organoid size difference from day 10, neocortical from day 30; SOX2+ rosette area at D30 24±3.07% in PCH2A vs 2±0.53% control, reversing by D50 (2±0.92% vs 12±1.24%); no significant apoptosis increase (kagermeier2024humanorganoidmodel pages 6-8, kagermeier2024humanorganoidmodel pages 8-10, kagermeier2024humanorganoidmodel pages 2-2, kagermeier2024humanorganoidmodel pages 1-2) (kagermeier2024humanorganoidmodel pages 6-8, kagermeier2024humanorganoidmodel pages 8-10, kagermeier2024humanorganoidmodel pages 2-2, kagermeier2024humanorganoidmodel pages 1-2, kagermeier2024humanorganoidmodel pages 2-4)
PCH6 / RARS2-associated disease RARS2; noncoding Kozak/promoter-5'UTR variant NM_020320.3:c.-2A>G causing major protein-level reduction Biallelic / autosomal recessive Pontocerebellar involvement with often rapid supratentorial atrophy; mitochondrial-disease context; diffusion imaging may help detect metabolic decompensation in mimics/related cases Early-onset encephalopathy with severe epilepsy/epileptic encephalopathy; may have lactic acidosis and mitochondrial respiratory chain defects, although lactic acidosis may be absent in some patients New 2023 paper reports an additional homozygous case with phenotype consistent with PCH6; prior work showed ~40% mRNA reduction, while this study showed a major decrease in protein translation due to Kozak disruption (ghasemi2024broadeningthephenotype pages 11-13, nicolle2023anoncodingvariant pages 1-2) (ghasemi2024broadeningthephenotype pages 11-13, nicolle2023anoncodingvariant pages 1-2, dijk2018what’snewin pages 6-7, kukulka2025pontocerebellarhypoplasiaa pages 6-7)
PCH1B / EXOSC3-associated disease EXOSC3; recurrent missense variants include c.395A>C (p.Asp132Ala) and c.572G>A (p.Gly191Asp) Autosomal recessive Often “butterfly” cerebellar pattern; hypoplasia/atrophy of pons and cerebellum with vermis and hemispheres similarly affected; intracerebellar cysts less common PCH1 phenotype with anterior horn involvement/motor neuron disease spectrum, hypotonia, weakness, respiratory insufficiency, congenital contractures; some genotypes milder and longer-surviving EXOSC3 variants account for about half of PCH1 in older literature; reported mean age at death 9 months in EXOSC3-mutated cases vs 3 months in non-EXOSC3 PCH1 in one review summary; in Turkish cohort EXOSC3 cases were 10.9% (dijk2018what’snewin pages 3-5, cavusoglu2024evaluationofthe pages 10-11, baas2020exosc3pontocerebellarhypoplasia pages 1-4) (dijk2018what’snewin pages 3-5, cavusoglu2024evaluationofthe pages 10-11, baas2020exosc3pontocerebellarhypoplasia pages 1-4)
PCH9 / AMPD2-associated disease AMPD2; multiple homozygous variants reported across series Autosomal recessive Dragonfly cerebellar atrophy/hypoplasia, reduced pons and middle cerebellar peduncles, “figure-of-8” midbrain, severe white-matter loss/periventricular leukomalacia-like change, thin/absent corpus callosum Severe prenatal/early infantile neurodevelopmental disorder with profound delay and microcephaly MRI phenotype reported as consistent across small published case series; Turkish cohort also linked AMPD2 with dragonfly/figure-of-8 patterns (cavusoglu2024evaluationofthe pages 1-2, cavusoglu2024evaluationofthe pages 11-12) (cavusoglu2024evaluationofthe pages 1-2, cavusoglu2024evaluationofthe pages 11-12, dijk2018what’snewin pages 6-7)
General mechanistic framework (van Dijk 2018; Namavar 2011) Many genes converge on RNA processing / translation / tRNA biology: TSEN54, TSEN2, TSEN34, TSEN15, CLP1, RARS2, EXOSC3, EXOSC8, EXOSC9; additional non-RNA genes include AMPD2, CHMP1A, SLC25A46, PCLO Classical PCH subtypes described as largely autosomal recessive Shared core pattern is pontine + cerebellar hypoplasia/atrophy, often with progressive microcephaly and variable supratentorial abnormalities Severe motor/cognitive disability, feeding/swallowing dysfunction, epilepsy, poor developmental progress; PCH1 includes spinal motor neuron degeneration; prognosis generally poor Older synthesis: incidence of each subtype unknown; most patients die in infancy or childhood; 2018 review notes 17 PCH-related genes in OMIM at that time, while later reviews report 17 types / 25 genes or more depending on classification date (ghasemi2024broadeningthephenotype pages 1-2, dijk2018what’snewin pages 1-3, dijk2018what’snewin pages 10-11) (ghasemi2024broadeningthephenotype pages 1-2, dijk2018what’snewin pages 1-3, dijk2018what’snewin pages 10-11)

Table: This table condenses the major PCH entities and evidence types retrieved, linking genes, imaging patterns, clinical manifestations, and the most useful recent quantitative findings. It is designed as a high-density reference for disease knowledge base curation and evidence tracing.

Key URLs and publication dates (from retrieved records)

Limitations of this report

  • The retrieved evidence did not include explicit OMIM/Orphanet/ICD/MeSH/MONDO identifiers or PMIDs in the text excerpts; therefore, identifier code strings and PMID-based citations could not be provided from tool evidence and should be supplemented by direct queries to OMIM/Orphanet/NCBI MeSH. (cavusoglu2024evaluationofthe pages 1-2, kukulka2025pontocerebellarhypoplasiaa pages 11-13)
  • Epidemiologic prevalence/incidence and variant carrier frequency data were not present in the retrieved excerpts. ()

References

  1. (cavusoglu2024evaluationofthe pages 1-2): Dilek Cavusoglu, Gulten Ozturk, Dilsad Turkdogan, Semra Hiz Kurul, Uluc Yis, Mustafa Komur, Faruk Incecik, Bulent Kara, Turkan Sahin, Olcay Unver, Cengiz Dilber, Gulen Gul Mert, Cagatay Gunay, Gamze Sarikaya Uzan, Ozlem Ersoy, Yavuz Oktay, Serdar Mermer, Gokcen Oz Tuncer, Olcay Gungor, Gul Demet Kaya Ozcora, Ugur Gumus, Ozlem Sezer, Gokhan Ozan Cetin, Fatma Demir, Arzu Yilmaz, Gurkan Gurbuz, Meral Topcu, Haluk Topaloglu, Ahmet Cevdet Ceylan, Serdar Ceylaner, Joseph G. Gleeson, Dilara Fusun Icagasioglu, and F. Mujgan Sonmez. Evaluation of the patients with the diagnosis of pontocerebellar hypoplasia: a multicenter national study. Cerebellum (London, England), 23:1950-1965, Apr 2024. URL: https://doi.org/10.1007/s12311-024-01690-1, doi:10.1007/s12311-024-01690-1. This article has 10 citations.

  2. (kukulka2025pontocerebellarhypoplasiaa pages 11-13): Natalie A Kukulka, Shriya Singh, Matthew T Whitehead, William B Dobyns, Taeun Chang, and Youssef A Kousa. Pontocerebellar hypoplasia: a review from 1912 to 2022. Brain Communications, Aug 2025. URL: https://doi.org/10.1093/braincomms/fcaf298, doi:10.1093/braincomms/fcaf298. This article has 3 citations and is from a peer-reviewed journal.

  3. (dijk2018what’snewin pages 1-3): Tessa van Dijk, Frank Baas, Peter G. Barth, and Bwee Tien Poll-The. What’s new in pontocerebellar hypoplasia? an update on genes and subtypes. Orphanet Journal of Rare Diseases, Jun 2018. URL: https://doi.org/10.1186/s13023-018-0826-2, doi:10.1186/s13023-018-0826-2. This article has 187 citations and is from a peer-reviewed journal.

  4. (zakaria2024classic“pch”genes pages 1-4): Rohaya Binti Mohamad Zakaria, Maisa Malta, Felixe Pelletier, Nassima Addour-Boudrahem, Elana Pinchefsky, Christine Saint Martin, and Myriam Srour. Classic “pch” genes are a rare cause of radiologic pontocerebellar hypoplasia. The Cerebellum, pages 1-13, Mar 2024. URL: https://doi.org/10.1007/s12311-023-01544-2, doi:10.1007/s12311-023-01544-2. This article has 6 citations.

  5. (kukulka2025pontocerebellarhypoplasiaa pages 13-14): Natalie A Kukulka, Shriya Singh, Matthew T Whitehead, William B Dobyns, Taeun Chang, and Youssef A Kousa. Pontocerebellar hypoplasia: a review from 1912 to 2022. Brain Communications, Aug 2025. URL: https://doi.org/10.1093/braincomms/fcaf298, doi:10.1093/braincomms/fcaf298. This article has 3 citations and is from a peer-reviewed journal.

  6. (kagermeier2024humanorganoidmodel pages 1-2): Theresa Kagermeier, Stefan Hauser, Kseniia Sarieva, Lucia Laugwitz, Samuel Groeschel, Wibke G. Janzarik, Zeynep Yentür, Katharina Becker, Ludger Schöls, Ingeborg Krägeloh-Mann, and Simone Mayer. Human organoid model of pontocerebellar hypoplasia 2a recapitulates brain region-specific size differences. Disease Models & Mechanisms, Jul 2024. URL: https://doi.org/10.1242/dmm.050740, doi:10.1242/dmm.050740. This article has 10 citations and is from a domain leading peer-reviewed journal.

  7. (NCT04378075 chunk 1): A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy. PTC Therapeutics. 2020. ClinicalTrials.gov Identifier: NCT04378075

  8. (NCT03572868 chunk 1): Long-term Outcome of Newborns With an Isolated Small Cerebellum. Hospices Civils de Lyon. 2018. ClinicalTrials.gov Identifier: NCT03572868

  9. (dijk2018what’snewin pages 10-11): Tessa van Dijk, Frank Baas, Peter G. Barth, and Bwee Tien Poll-The. What’s new in pontocerebellar hypoplasia? an update on genes and subtypes. Orphanet Journal of Rare Diseases, Jun 2018. URL: https://doi.org/10.1186/s13023-018-0826-2, doi:10.1186/s13023-018-0826-2. This article has 187 citations and is from a peer-reviewed journal.

  10. (ghasemi2024broadeningthephenotype pages 11-13): Mohammad-Reza Ghasemi, Sahand Tehrani Fateh, Aysan Moeinafshar, Hossein Sadeghi, Parvaneh Karimzadeh, Reza Mirfakhraie, Mitra Rezaei, Farzad Hashemi-Gorji, Morteza Rezvani Kashani, Fatemehsadat Fazeli Bavandpour, Saman Bagheri, Parinaz Moghimi, Masoumeh Rostami, Rasoul Madannejad, Hassan Roudgari, and Mohammad Miryounesi. Broadening the phenotype and genotype spectrum of novel mutations in pontocerebellar hypoplasia with a comprehensive molecular literature review. BMC Medical Genomics, Feb 2024. URL: https://doi.org/10.1186/s12920-024-01810-0, doi:10.1186/s12920-024-01810-0. This article has 13 citations and is from a peer-reviewed journal.

  11. (zakaria2024classic“pch”genes pages 17-20): Rohaya Binti Mohamad Zakaria, Maisa Malta, Felixe Pelletier, Nassima Addour-Boudrahem, Elana Pinchefsky, Christine Saint Martin, and Myriam Srour. Classic “pch” genes are a rare cause of radiologic pontocerebellar hypoplasia. The Cerebellum, pages 1-13, Mar 2024. URL: https://doi.org/10.1007/s12311-023-01544-2, doi:10.1007/s12311-023-01544-2. This article has 6 citations.

  12. (zakaria2024classic“pch”genes pages 4-7): Rohaya Binti Mohamad Zakaria, Maisa Malta, Felixe Pelletier, Nassima Addour-Boudrahem, Elana Pinchefsky, Christine Saint Martin, and Myriam Srour. Classic “pch” genes are a rare cause of radiologic pontocerebellar hypoplasia. The Cerebellum, pages 1-13, Mar 2024. URL: https://doi.org/10.1007/s12311-023-01544-2, doi:10.1007/s12311-023-01544-2. This article has 6 citations.

  13. (cavusoglu2024evaluationofthe pages 2-5): Dilek Cavusoglu, Gulten Ozturk, Dilsad Turkdogan, Semra Hiz Kurul, Uluc Yis, Mustafa Komur, Faruk Incecik, Bulent Kara, Turkan Sahin, Olcay Unver, Cengiz Dilber, Gulen Gul Mert, Cagatay Gunay, Gamze Sarikaya Uzan, Ozlem Ersoy, Yavuz Oktay, Serdar Mermer, Gokcen Oz Tuncer, Olcay Gungor, Gul Demet Kaya Ozcora, Ugur Gumus, Ozlem Sezer, Gokhan Ozan Cetin, Fatma Demir, Arzu Yilmaz, Gurkan Gurbuz, Meral Topcu, Haluk Topaloglu, Ahmet Cevdet Ceylan, Serdar Ceylaner, Joseph G. Gleeson, Dilara Fusun Icagasioglu, and F. Mujgan Sonmez. Evaluation of the patients with the diagnosis of pontocerebellar hypoplasia: a multicenter national study. Cerebellum (London, England), 23:1950-1965, Apr 2024. URL: https://doi.org/10.1007/s12311-024-01690-1, doi:10.1007/s12311-024-01690-1. This article has 10 citations.

  14. (ghasemi2024broadeningthephenotype pages 1-2): Mohammad-Reza Ghasemi, Sahand Tehrani Fateh, Aysan Moeinafshar, Hossein Sadeghi, Parvaneh Karimzadeh, Reza Mirfakhraie, Mitra Rezaei, Farzad Hashemi-Gorji, Morteza Rezvani Kashani, Fatemehsadat Fazeli Bavandpour, Saman Bagheri, Parinaz Moghimi, Masoumeh Rostami, Rasoul Madannejad, Hassan Roudgari, and Mohammad Miryounesi. Broadening the phenotype and genotype spectrum of novel mutations in pontocerebellar hypoplasia with a comprehensive molecular literature review. BMC Medical Genomics, Feb 2024. URL: https://doi.org/10.1186/s12920-024-01810-0, doi:10.1186/s12920-024-01810-0. This article has 13 citations and is from a peer-reviewed journal.

  15. (cavusoglu2024evaluationofthe pages 11-12): Dilek Cavusoglu, Gulten Ozturk, Dilsad Turkdogan, Semra Hiz Kurul, Uluc Yis, Mustafa Komur, Faruk Incecik, Bulent Kara, Turkan Sahin, Olcay Unver, Cengiz Dilber, Gulen Gul Mert, Cagatay Gunay, Gamze Sarikaya Uzan, Ozlem Ersoy, Yavuz Oktay, Serdar Mermer, Gokcen Oz Tuncer, Olcay Gungor, Gul Demet Kaya Ozcora, Ugur Gumus, Ozlem Sezer, Gokhan Ozan Cetin, Fatma Demir, Arzu Yilmaz, Gurkan Gurbuz, Meral Topcu, Haluk Topaloglu, Ahmet Cevdet Ceylan, Serdar Ceylaner, Joseph G. Gleeson, Dilara Fusun Icagasioglu, and F. Mujgan Sonmez. Evaluation of the patients with the diagnosis of pontocerebellar hypoplasia: a multicenter national study. Cerebellum (London, England), 23:1950-1965, Apr 2024. URL: https://doi.org/10.1007/s12311-024-01690-1, doi:10.1007/s12311-024-01690-1. This article has 10 citations.

  16. (nicolle2023anoncodingvariant pages 1-2): Romain Nicolle, Nami Altin, Karine Siquier-Pernet, Sherlina Salignac, Pierre Blanc, Arnold Munnich, Christine Bole-Feysot, Valérie Malan, Barthélémy Caron, Patrick Nitschké, Isabelle Desguerre, Nathalie Boddaert, Marlène Rio, Antonio Rausell, and Vincent Cantagrel. A non-coding variant in the kozak sequence of rars2 strongly decreases protein levels and causes pontocerebellar hypoplasia. BMC Medical Genomics, Jun 2023. URL: https://doi.org/10.1186/s12920-023-01582-z, doi:10.1186/s12920-023-01582-z. This article has 7 citations and is from a peer-reviewed journal.

  17. (cavusoglu2024evaluationofthe pages 10-11): Dilek Cavusoglu, Gulten Ozturk, Dilsad Turkdogan, Semra Hiz Kurul, Uluc Yis, Mustafa Komur, Faruk Incecik, Bulent Kara, Turkan Sahin, Olcay Unver, Cengiz Dilber, Gulen Gul Mert, Cagatay Gunay, Gamze Sarikaya Uzan, Ozlem Ersoy, Yavuz Oktay, Serdar Mermer, Gokcen Oz Tuncer, Olcay Gungor, Gul Demet Kaya Ozcora, Ugur Gumus, Ozlem Sezer, Gokhan Ozan Cetin, Fatma Demir, Arzu Yilmaz, Gurkan Gurbuz, Meral Topcu, Haluk Topaloglu, Ahmet Cevdet Ceylan, Serdar Ceylaner, Joseph G. Gleeson, Dilara Fusun Icagasioglu, and F. Mujgan Sonmez. Evaluation of the patients with the diagnosis of pontocerebellar hypoplasia: a multicenter national study. Cerebellum (London, England), 23:1950-1965, Apr 2024. URL: https://doi.org/10.1007/s12311-024-01690-1, doi:10.1007/s12311-024-01690-1. This article has 10 citations.

  18. (kagermeier2024humanorganoidmodel pages 6-8): Theresa Kagermeier, Stefan Hauser, Kseniia Sarieva, Lucia Laugwitz, Samuel Groeschel, Wibke G. Janzarik, Zeynep Yentür, Katharina Becker, Ludger Schöls, Ingeborg Krägeloh-Mann, and Simone Mayer. Human organoid model of pontocerebellar hypoplasia 2a recapitulates brain region-specific size differences. Disease Models & Mechanisms, Jul 2024. URL: https://doi.org/10.1242/dmm.050740, doi:10.1242/dmm.050740. This article has 10 citations and is from a domain leading peer-reviewed journal.

  19. (dijk2018what’snewin pages 6-7): Tessa van Dijk, Frank Baas, Peter G. Barth, and Bwee Tien Poll-The. What’s new in pontocerebellar hypoplasia? an update on genes and subtypes. Orphanet Journal of Rare Diseases, Jun 2018. URL: https://doi.org/10.1186/s13023-018-0826-2, doi:10.1186/s13023-018-0826-2. This article has 187 citations and is from a peer-reviewed journal.

  20. (kagermeier2024humanorganoidmodel pages 2-4): Theresa Kagermeier, Stefan Hauser, Kseniia Sarieva, Lucia Laugwitz, Samuel Groeschel, Wibke G. Janzarik, Zeynep Yentür, Katharina Becker, Ludger Schöls, Ingeborg Krägeloh-Mann, and Simone Mayer. Human organoid model of pontocerebellar hypoplasia 2a recapitulates brain region-specific size differences. Disease Models & Mechanisms, Jul 2024. URL: https://doi.org/10.1242/dmm.050740, doi:10.1242/dmm.050740. This article has 10 citations and is from a domain leading peer-reviewed journal.

  21. (dijk2018what’snewin pages 13-14): Tessa van Dijk, Frank Baas, Peter G. Barth, and Bwee Tien Poll-The. What’s new in pontocerebellar hypoplasia? an update on genes and subtypes. Orphanet Journal of Rare Diseases, Jun 2018. URL: https://doi.org/10.1186/s13023-018-0826-2, doi:10.1186/s13023-018-0826-2. This article has 187 citations and is from a peer-reviewed journal.

  22. (kukulka2025pontocerebellarhypoplasiaa pages 6-7): Natalie A Kukulka, Shriya Singh, Matthew T Whitehead, William B Dobyns, Taeun Chang, and Youssef A Kousa. Pontocerebellar hypoplasia: a review from 1912 to 2022. Brain Communications, Aug 2025. URL: https://doi.org/10.1093/braincomms/fcaf298, doi:10.1093/braincomms/fcaf298. This article has 3 citations and is from a peer-reviewed journal.

  23. (NCT04378075 chunk 2): A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy. PTC Therapeutics. 2020. ClinicalTrials.gov Identifier: NCT04378075

  24. (kagermeier2024humanorganoidmodel pages 2-2): Theresa Kagermeier, Stefan Hauser, Kseniia Sarieva, Lucia Laugwitz, Samuel Groeschel, Wibke G. Janzarik, Zeynep Yentür, Katharina Becker, Ludger Schöls, Ingeborg Krägeloh-Mann, and Simone Mayer. Human organoid model of pontocerebellar hypoplasia 2a recapitulates brain region-specific size differences. Disease Models & Mechanisms, Jul 2024. URL: https://doi.org/10.1242/dmm.050740, doi:10.1242/dmm.050740. This article has 10 citations and is from a domain leading peer-reviewed journal.

  25. (cavusoglu2024evaluationofthe pages 12-14): Dilek Cavusoglu, Gulten Ozturk, Dilsad Turkdogan, Semra Hiz Kurul, Uluc Yis, Mustafa Komur, Faruk Incecik, Bulent Kara, Turkan Sahin, Olcay Unver, Cengiz Dilber, Gulen Gul Mert, Cagatay Gunay, Gamze Sarikaya Uzan, Ozlem Ersoy, Yavuz Oktay, Serdar Mermer, Gokcen Oz Tuncer, Olcay Gungor, Gul Demet Kaya Ozcora, Ugur Gumus, Ozlem Sezer, Gokhan Ozan Cetin, Fatma Demir, Arzu Yilmaz, Gurkan Gurbuz, Meral Topcu, Haluk Topaloglu, Ahmet Cevdet Ceylan, Serdar Ceylaner, Joseph G. Gleeson, Dilara Fusun Icagasioglu, and F. Mujgan Sonmez. Evaluation of the patients with the diagnosis of pontocerebellar hypoplasia: a multicenter national study. Cerebellum (London, England), 23:1950-1965, Apr 2024. URL: https://doi.org/10.1007/s12311-024-01690-1, doi:10.1007/s12311-024-01690-1. This article has 10 citations.

  26. (dijk2018what’snewin pages 3-5): Tessa van Dijk, Frank Baas, Peter G. Barth, and Bwee Tien Poll-The. What’s new in pontocerebellar hypoplasia? an update on genes and subtypes. Orphanet Journal of Rare Diseases, Jun 2018. URL: https://doi.org/10.1186/s13023-018-0826-2, doi:10.1186/s13023-018-0826-2. This article has 187 citations and is from a peer-reviewed journal.

  27. (ghasemi2024broadeningthephenotype pages 6-7): Mohammad-Reza Ghasemi, Sahand Tehrani Fateh, Aysan Moeinafshar, Hossein Sadeghi, Parvaneh Karimzadeh, Reza Mirfakhraie, Mitra Rezaei, Farzad Hashemi-Gorji, Morteza Rezvani Kashani, Fatemehsadat Fazeli Bavandpour, Saman Bagheri, Parinaz Moghimi, Masoumeh Rostami, Rasoul Madannejad, Hassan Roudgari, and Mohammad Miryounesi. Broadening the phenotype and genotype spectrum of novel mutations in pontocerebellar hypoplasia with a comprehensive molecular literature review. BMC Medical Genomics, Feb 2024. URL: https://doi.org/10.1186/s12920-024-01810-0, doi:10.1186/s12920-024-01810-0. This article has 13 citations and is from a peer-reviewed journal.

  28. (kagermeier2024humanorganoidmodel pages 8-10): Theresa Kagermeier, Stefan Hauser, Kseniia Sarieva, Lucia Laugwitz, Samuel Groeschel, Wibke G. Janzarik, Zeynep Yentür, Katharina Becker, Ludger Schöls, Ingeborg Krägeloh-Mann, and Simone Mayer. Human organoid model of pontocerebellar hypoplasia 2a recapitulates brain region-specific size differences. Disease Models & Mechanisms, Jul 2024. URL: https://doi.org/10.1242/dmm.050740, doi:10.1242/dmm.050740. This article has 10 citations and is from a domain leading peer-reviewed journal.

  29. (baas2020exosc3pontocerebellarhypoplasia pages 1-4): F Baas and T van Dijk. Exosc3 pontocerebellar hypoplasia. Unknown journal, 2020.